Aktienanalyse zu Pacific Biosciences of California Inc (PACB)PACBPacific Biosciences of California Inc

Pacific Biosciences of California, Inc. is a life science technology company. The Company designs, develops, and manufactures sequencing solutions. Its products and technology include HiFi long-read sequencing technology, which addresses a set of applications including human germline sequencing, plant and animal sciences, infectious disease, microbiology, oncology, and other applications. Its sequencing technology supports oncology research by enabling analysis of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), providing researchers with insight into cancer biology. It focuses on creating sequencing systems to provide customers with a view of genomes, transcriptomes, and epigenomes. Its customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Given the current price of $1.73 and the RSI at 24.595, which indicates the stock is oversold, it might seem like a potential buy. However, the significant risks include a recent 25.75% drop over the last five days and a lowered revenue guidance for 2026 to between $155 million and $165 million, down from $165 million to $175 million. These factors suggest that the stock may continue to face downward pressure, making it a risky investment at this time.

6 analysts cover PACB: 2 rate it Buy, 4 Hold and 0 Sell. The average price target is 2.40.